These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 22309666)

  • 1. Immunosenescence and herd immunity: with an ever-increasing aging population do we need to rethink vaccine schedules?
    Lang PO; Aspinall R
    Expert Rev Vaccines; 2012 Feb; 11(2):167-76. PubMed ID: 22309666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunosenescence: Implications for vaccination programmes in adults.
    Lang PO; Govind S; Michel JP; Aspinall R; Mitchell WA
    Maturitas; 2011 Apr; 68(4):322-30. PubMed ID: 21316879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune senescence and vaccination in the elderly.
    Lang PO; Govind S; Bokum AT; Kenny N; Matas E; Pitts D; Aspinall R
    Curr Top Med Chem; 2013; 13(20):2541-50. PubMed ID: 24066892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination and herd immunity: what more do we know?
    Rashid H; Khandaker G; Booy R
    Curr Opin Infect Dis; 2012 Jun; 25(3):243-9. PubMed ID: 22561998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine.
    Isaacman DJ; Strutton DR; Kalpas EA; Horowicz-Mehler N; Stern LS; Casciano R; Ciuryla V
    Clin Ther; 2008 Feb; 30(2):341-57. PubMed ID: 18343273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of vaccines: our nation's front line against infectious diseases.
    Gellin B; Landry S
    Clin Pharmacol Ther; 2010 Nov; 88(5):580-1. PubMed ID: 20959840
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of surveillance in assuring mutual protection for vaccine-preventable diseases.
    Lopalco PL
    Clin Microbiol Infect; 2016 Dec; 22 Suppl 5():S85-S88. PubMed ID: 27476865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.
    Lloyd A; Patel N; Scott DA; Runge C; Claes C; Rose M
    Eur J Health Econ; 2008 Feb; 9(1):7-15. PubMed ID: 17333089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Progress in assessment of vaccine on herd protection].
    Jin PF; Li JX; Zhu FC
    Zhonghua Liu Xing Bing Xue Za Zhi; 2018 Jun; 39(6):862-866. PubMed ID: 29936762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Herd immunity: recent uses in vaccine assessment.
    Gonçalves G
    Expert Rev Vaccines; 2008 Dec; 7(10):1493-506. PubMed ID: 19053206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Herd immunity and pneumococcal conjugate vaccine: a quantitative model.
    Haber M; Barskey A; Baughman W; Barker L; Whitney CG; Shaw KM; Orenstein W; Stephens DS
    Vaccine; 2007 Jul; 25(29):5390-8. PubMed ID: 17583392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential approaches for vaccination from childhood to old age.
    Prelog M
    Gerontology; 2013; 59(3):230-9. PubMed ID: 23183353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-related changes in immunity: implications for vaccination in the elderly.
    Kovaiou RD; Herndler-Brandstetter D; Grubeck-Loebenstein B
    Expert Rev Mol Med; 2007 Feb; 9(3):1-17. PubMed ID: 17266794
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indirect effects by meningococcal vaccines: herd protection versus herd immunity.
    Bröker M
    Hum Vaccin; 2011 Aug; 7(8):881-2. PubMed ID: 21785283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biology of immune responses to vaccines in elderly persons.
    Weinberger B; Herndler-Brandstetter D; Schwanninger A; Weiskopf D; Grubeck-Loebenstein B
    Clin Infect Dis; 2008 Apr; 46(7):1078-84. PubMed ID: 18444828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
    Melegaro A; Edmunds WJ
    Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges in adult vaccination.
    de Gomensoro E; Del Giudice G; Doherty TM
    Ann Med; 2018 May; 50(3):181-192. PubMed ID: 29338438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age-related decline in immunity: implications for vaccine responsiveness.
    Kumar R; Burns EA
    Expert Rev Vaccines; 2008 May; 7(4):467-79. PubMed ID: 18444893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.